Clinical Trials Logo

Stage 0a Bladder Cancer AJCC v8 clinical trials

View clinical trials related to Stage 0a Bladder Cancer AJCC v8.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06350734 Recruiting - Clinical trials for Stage IIIA Bladder Cancer AJCC v8

Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study

Start date: October 12, 2018
Phase:
Study type: Observational

This study evaluates the effect of bladder cancer treatment on quality of life.

NCT ID: NCT06173349 Recruiting - Clinical trials for Stage 0a Bladder Cancer AJCC v8

PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer

Start date: November 22, 2023
Phase: Phase 1
Study type: Interventional

This phase I trial tests the safety, tolerability and effectiveness of PLZ4-coated paclitacel-loaded micelles (PPM) in treating patients with non-muscle invasive bladder cancer that has come back after a period of improvement (recurrent) or that does not respond to treatment (refractory). PPM is a bladder cancer-specific nanoparticle that can specifically target and deliver treatment to the tumor cells in the bladder. PPM contains paclitaxel, which is a drug that kills tumor cells or keeps them from growing.

NCT ID: NCT05843448 Recruiting - Clinical trials for Stage 0a Bladder Cancer AJCC v8

IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer

Start date: April 19, 2023
Phase: Phase 1
Study type: Interventional

This phase I trial tests the safety and side effects of a PD-L1/IDO peptide vaccine (IO102-IO103) in combination with pembrolizumab in treating patients with non-muscle invasive bladder cancer. IO102-IO103 is a novel IDO and PD-L1 peptide based immune-modulatory therapeutic. It is designed to activate the patient's own immune cells (called T-cells) to fight the tumor and stop the tumor cells escaping from the body's immune system. IO102-IO103 works to directly kill tumor cells and remove the body's immune suppressive cells, which are cells that prevent the immune system from fighting the tumor. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving IO102-IO103 in combination with pembrolizumab may make tumor cells more visible/recognizable to the immune system.

NCT ID: NCT04164082 Recruiting - Clinical trials for Stage 0a Bladder Cancer AJCC v8

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Start date: March 18, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial studies the effect of adding pembrolizumab to gemcitabine in treating patients with non-muscle invasive bladder cancer whose cancer does not respond to Bacillus Calmette-Guerin (BCG) treatment. Chemotherapy drugs, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the patient's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Adding pembrolizumab to gemcitabine may delay the return of BCG-unresponsive bladder cancer for longer period compared to gemcitabine alone.